BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Globenewswire·2026-01-13 21:05
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on January 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of an individual hired by BBOT in December 2025. The employee received non-qualified stock options to purchase 129,090 shares of BBOT common stock, par value $0.0 ...